Keyword: Yescarta (axicabtagene ciloleucel)
Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.
NICE may have rejected it, but thanks to a new discount, Yescarta's beating archrival Kymriah to adult lymphoma patients on England's health service.
NICE rejected Novartis' Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.
Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
In a busy week at the European Commission, Novartis’ Kymriah, Gilead’s Yescarta, Jazz's Vyxeos, Alnylam's Onpattro and others got approvals.
Gilead has some big commercial challenges looming, and it’s poached an Amgen executive to spearhead them.
The CAR-T drug is a "step-change" for patients with no other options, but it's too pricey to cover routinely, the cost watchdog said.
Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.
Gilead and Novartis CAR-T cancer drugs Yescarta and Kymriah won an EMA committee backing for marketing approval.